203 related articles for article (PubMed ID: 24889897)
21. Potential new antitumor agents from an innovative combination of camphorato, a ramification of traditional Chinese medicine, with a platinum moiety.
Wang L; Gou S; Chen Y; Liu Y
Bioorg Med Chem Lett; 2005 Jul; 15(14):3417-22. PubMed ID: 15953727
[TBL] [Abstract][Full Text] [Related]
22. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
23. Identification of an iridium(III) complex with anti-bacterial and anti-cancer activity.
Lu L; Liu LJ; Chao WC; Zhong HJ; Wang M; Chen XP; Lu JJ; Li RN; Ma DL; Leung CH
Sci Rep; 2015 Sep; 5():14544. PubMed ID: 26416333
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, structure and antitumor activity of [RhCl3(N-N)(DMSO)] polypyridyl complexes.
Sliwińska U; Pruchnik FP; Pelińska I; Ułaszewski S; Wilczok A; Zajdel A
J Inorg Biochem; 2008 Oct; 102(10):1947-51. PubMed ID: 18718669
[TBL] [Abstract][Full Text] [Related]
25. Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes.
Boff B; Gaiddon C; Pfeffer M
Inorg Chem; 2013 Mar; 52(5):2705-15. PubMed ID: 23427955
[TBL] [Abstract][Full Text] [Related]
26. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT
Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the anti-neoplastic effects of dirhodium(II) tetrapropionate and its adducts with nicotinate and isonicotinate anions in mice bearing Ehrlich tumors.
de Souza AR; Coelho EP; Zyngier SB
Eur J Med Chem; 2006 Oct; 41(10):1214-6. PubMed ID: 16822594
[TBL] [Abstract][Full Text] [Related]
28. Ruthenium porphyrin compounds for photodynamic therapy of cancer.
Schmitt F; Govindaswamy P; Süss-Fink G; Ang WH; Dyson PJ; Juillerat-Jeanneret L; Therrien B
J Med Chem; 2008 Mar; 51(6):1811-6. PubMed ID: 18298056
[TBL] [Abstract][Full Text] [Related]
29. Luminescent cyclometalated iridium(III) polypyridine di-2-picolylamine complexes: synthesis, photophysics, electrochemistry, cation binding, cellular internalization, and cytotoxic activity.
Lee PK; Law WH; Liu HW; Lo KK
Inorg Chem; 2011 Sep; 50(17):8570-9. PubMed ID: 21834537
[TBL] [Abstract][Full Text] [Related]
30. Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity.
Lu X; Wu YM; Yang JM; Ma FE; Li LP; Chen S; Zhang Y; Ni QL; Pan YM; Hong X; Peng Y
Eur J Med Chem; 2018 May; 151():226-236. PubMed ID: 29614419
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation.
Ashizawa T; Miyata H; Ishii H; Oshita C; Matsuno K; Masuda Y; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Akiyama Y
Int J Oncol; 2011 May; 38(5):1245-52. PubMed ID: 21369699
[TBL] [Abstract][Full Text] [Related]
32. Highly potent extranuclear-targeted luminescent iridium(iii) antitumor agents containing benzimidazole-based ligands with a handle for functionalization.
Yellol J; Pérez SA; Yellol G; Zajac J; Donaire A; Vigueras G; Novohradsky V; Janiak C; Brabec V; Ruiz J
Chem Commun (Camb); 2016 Dec; 52(98):14165-14168. PubMed ID: 27869279
[TBL] [Abstract][Full Text] [Related]
33. Tracking of STAT3 signaling for anticancer drug-discovery based on localized surface plasmon resonance.
Song S; Nguyen AH; Lee JU; Cha M; Sim SJ
Analyst; 2016 Apr; 141(8):2493-501. PubMed ID: 26998671
[TBL] [Abstract][Full Text] [Related]
34. Novel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.
Ruiz J; Rodríguez V; Cutillas N; Samper KG; Capdevila M; Palacios Ò; Espinosa A
Dalton Trans; 2012 Nov; 41(41):12847-56. PubMed ID: 22983366
[TBL] [Abstract][Full Text] [Related]
35. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
[TBL] [Abstract][Full Text] [Related]
36. Antimelanomal activity of the copper(II) complexes of 1-substituted 5-amino-imidazole ligands against B16F10 mouse melanoma cells.
Sandbhor U; Kulkarni P; Padhye S; Kundu G; Mackenzie G; Pritchard R
Bioorg Med Chem Lett; 2004 Jun; 14(11):2877-82. PubMed ID: 15125951
[TBL] [Abstract][Full Text] [Related]
37. Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.
Cheng Y; Qi Y
Anticancer Agents Med Chem; 2017; 17(8):1046-1069. PubMed ID: 28270080
[TBL] [Abstract][Full Text] [Related]
38. The structural and functional roles of rhodium(II)-rhodium(II) dimers in multinuclear ruthenium(II) complexes.
Cooke MW; Hanan GS; Loiseau F; Campagna S; Watanabe M; Tanaka Y
Angew Chem Int Ed Engl; 2005 Aug; 44(31):4881-4. PubMed ID: 15995992
[No Abstract] [Full Text] [Related]
39. Rhodium and its compounds as potential agents in cancer treatment.
Katsaros N; Anagnostopoulou A
Crit Rev Oncol Hematol; 2002 Jun; 42(3):297-308. PubMed ID: 12050021
[TBL] [Abstract][Full Text] [Related]
40. Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.
Ludwig G; Mijatović S; Ranđelović I; Bulatović M; Miljković D; Maksimović-Ivanić D; Korb M; Lang H; Steinborn D; Kaluđerović GN
Eur J Med Chem; 2013 Nov; 69():216-22. PubMed ID: 24042044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
